Physician Profile

Jessica M. Clement, M.D.

Assistant Professor, Department of Medicine
Medical Director, Clinical Trials Office

Dr. Clement is an assistant professor of medicine in the Division of Hematology-Oncology and Neag Comprehensive Cancer Center. She specializes in the treatment of genitourinary (bladder, prostate, kidney, testicular) and gastrointestinal cancers.

Office Locations:

Neag Comprehensive Cancer Center
UConn Health
263 Farmington Avenue
Farmington, CT 06030

Board Certifications:
  • Internal Medicine
  • Hematology
  • Medical Oncology
Education and Training:
Undergraduate SchoolUnion CollegeBiology
Medical SchoolVirginia Commonwealth UniversityMedicine
InternshipBeth Israel Deaconess Medical CenterMedicine
ResidencyBeth Israel Deaconess Medical CenterMedicine
ResidencyBeth Israel Deaconess Medical CenterChief Resident, Internal Medicine
FellowshipBeth Israel Deaconess Medical CenterHematology-Oncology
Hospital Affiliation:
  • John Dempsey Hospital
Clinical Interests:

Genitourinary malignancies (bladder, prostate, kidney and testicular cancers).

Research Interests:

Dr. Clement is involved in bladder cancer research with Dr. John Taylor in the Division of Urologic Oncology.

Selected Publications:

Peer Reviewed Publications

Atypical presentation of fever as hypersensitivity reaction to oxaliplatin. Khurana, Arushi; Mitsis, Demytra; Kowlgi, Gurukripa N; Holle, Lisa M; Clement, Jessica M. (2014). Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,

Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Galsky, Matthew D; Hendricks, Ryan; Svatek, Robert; Bangs, Rick; Hoffman-Censits, Jean; Clement, Jessica; Dreicer, Robert; Guancial, Elizabeth; Hahn, Noah; Lerner, Seth P; O'Donnell, Peter H; Quale, Diane Zipursky; Siefker-Radtke, Arlene; Shipley, William; Sonpavde, Guru; Vaena, Daniel; Vinson, Jacob; Rosenberg, Jonathan. (2013). Cancer, 11, (119), 1994-8.

Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Hess, Gregory; Borker, Rohit; Fonseca, Eileen. (2013). Clinical genitourinary cancer, 2, (11), 161-7.

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. Choueiri, Toni K; Regan, Meredith M; Rosenberg, Jonathan E; Oh, William K; Clement, Jessica; Amato, Angela M; McDermott, David; Cho, Daniel C; Atkins, Michael B; Signoretti, Sabina. (2010). BJU international, 6, (106), 772-8.

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. Choueiri, Toni K; Duh, Mei Sheng; Clement, Jessica; Brick, Ashley J; Rogers, Miranda J; Kwabi, Christabel; Shah, Karishma; Percy, Andrew G; Antràs, Lucia; Jayawant, Sujata S; Chen, Kristina; Wang, Si-Tien; Luka, Andi; Neary, Maureen P; McDermott, David; Oh, William K. (2010). BJU international, 9, (105), 1247-54.